O	0	1	A
O	2	7	phase
O	7	8	-
O	8	11	III
O	12	22	prevention
O	23	28	trial
O	29	31	of
O	32	35	low
O	35	36	-
O	36	40	dose
B-intervention	41	50	tamoxifen
O	51	53	in
O	54	68	postmenopausal
O	69	76	hormone
O	77	88	replacement
O	89	96	therapy
O	97	102	users
O	102	103	:
O	104	107	the
O	108	111	HOT
O	112	117	study
O	117	118	.

O	119	133	Postmenopausal
O	134	141	hormone
O	142	153	replacement
O	154	161	therapy
O	162	163	(
O	163	166	HRT
O	166	167	)
O	168	176	relieves
O	177	187	menopausal
O	188	196	symptoms
O	197	200	and
O	201	204	may
O	205	213	decrease
O	214	223	mortality
O	224	226	in
O	227	235	recently
O	236	250	postmenopausal
O	251	256	women
O	256	257	,
O	258	261	but
O	262	271	increases
O	272	278	breast
O	279	285	cancer
O	286	290	risk
O	290	291	.

O	292	295	Low
O	295	296	-
O	296	300	dose
O	301	310	tamoxifen
O	311	314	has
O	315	320	shown
O	321	329	retained
O	330	338	activity
O	339	341	in
O	342	347	phase
O	347	348	-
O	348	350	II
O	351	358	studies
O	358	359	.

O	360	362	We
O	363	372	conducted
O	373	374	a
O	375	380	phase
O	380	381	-
O	381	384	III
O	385	390	trial
O	391	393	in
B-total-participants	394	398	1884
O	399	407	recently
O	408	422	postmenopausal
O	423	428	women
O	429	431	on
O	432	435	HRT
O	436	439	who
O	440	444	were
O	445	453	randomly
O	454	462	assigned
O	463	465	to
O	466	472	either
O	473	482	tamoxifen
O	482	483	,
O	484	485	5
O	486	488	mg
O	488	489	/
O	489	492	day
O	492	493	,
O	494	496	or
B-control	497	504	placebo
O	505	508	for
O	509	510	5
O	511	516	years
O	516	517	.

O	518	521	The
O	522	529	primary
O	530	533	end
O	534	539	point
O	540	543	was
B-outcome-Measure	544	550	breast
I-outcome-Measure	551	557	cancer
I-outcome-Measure	558	567	incidence
O	567	568	.

O	569	574	After
O	575	576	6
O	576	577	.
O	577	578	2
O	579	580	Â±
O	581	582	1
O	582	583	.
O	583	584	9
O	585	590	years
O	591	595	mean
O	596	602	follow
O	602	603	-
O	603	605	up
O	605	606	,
O	607	612	there
O	613	617	were
B-cv-bin-abs	618	620	24
B-outcome	621	627	breast
I-outcome	628	635	cancers
O	636	638	on
O	639	646	placebo
O	647	650	and
B-iv-bin-abs	651	653	19
O	654	656	on
O	657	666	tamoxifen
O	667	668	(
O	668	672	risk
O	673	678	ratio
O	678	679	,
O	680	682	RR
O	682	683	,
O	684	685	0
O	685	686	.
O	686	688	80
O	688	689	;
O	690	692	95
O	692	693	%
O	694	696	CI
O	697	698	0
O	698	699	.
O	699	701	44
O	701	702	-
O	702	703	1
O	703	704	.
O	704	706	46
O	706	707	)
O	707	708	.

O	709	718	Tamoxifen
O	719	725	showed
O	726	735	favorable
B-outcome	736	742	trends
I-outcome	743	745	in
I-outcome	746	753	luminal
I-outcome	753	754	-
I-outcome	754	755	A
I-outcome	756	762	tumors
O	763	764	(
O	764	766	RR
O	766	767	,
O	768	769	0
O	769	770	.
O	770	772	32
O	772	773	;
O	774	776	95
O	776	777	%
O	778	780	CI
O	781	782	0
O	782	783	.
O	783	785	12
O	785	786	-
O	786	787	0
O	787	788	.
O	788	790	86
O	790	791	)
O	791	792	,
O	793	795	in
O	796	799	HRT
O	800	805	users
O	806	807	<
O	807	808	5
O	809	814	years
O	815	816	(
O	816	818	RR
O	818	819	,
O	820	821	0
O	821	822	.
O	822	824	35
O	824	825	;
O	826	828	95
O	828	829	%
O	830	832	CI
O	833	834	0
O	834	835	.
O	835	837	15
O	837	838	-
O	838	839	0
O	839	840	.
O	840	842	82
O	842	843	)
O	844	847	and
O	848	850	in
O	851	856	women
O	857	867	completing
O	868	870	at
O	871	876	least
O	877	879	12
O	880	886	months
O	887	889	of
O	890	899	treatment
O	900	901	(
O	901	903	RR
O	903	904	,
O	905	906	0
O	906	907	.
O	907	909	49
O	909	910	;
O	911	913	95
O	913	914	%
O	915	917	CI
O	918	919	0
O	919	920	.
O	920	922	23
O	922	923	-
O	923	924	1
O	924	925	.
O	925	927	02
O	927	928	)
O	928	929	.

O	930	937	Serious
O	938	945	adverse
O	946	952	events
O	953	956	did
O	957	960	not
O	961	967	differ
O	968	975	between
O	976	983	placebo
O	984	987	and
O	988	997	tamoxifen
O	997	998	,
O	999	1008	including
O	1008	1009	,
O	1010	1022	respectively
O	1022	1023	,
B-outcome	1024	1032	coronary
I-outcome	1033	1038	heart
I-outcome	1039	1047	syndrome
O	1048	1049	(
B-cv-bin-abs	1049	1050	6
O	1051	1057	versus
B-iv-bin-abs	1058	1059	4
O	1059	1060	)
O	1060	1061	,
B-outcome	1062	1077	cerebrovascular
I-outcome	1078	1084	events
O	1085	1086	(
B-cv-bin-abs	1086	1087	2
O	1088	1094	versus
B-iv-bin-abs	1095	1096	5
O	1096	1097	)
O	1097	1098	,
B-outcome	1099	1102	VTE
O	1103	1104	(
B-cv-bin-abs	1104	1105	2
O	1106	1112	versus
B-iv-bin-abs	1113	1114	5
O	1114	1115	)
O	1116	1119	and
B-outcome	1120	1127	uterine
I-outcome	1128	1135	cancers
O	1136	1137	(
B-cv-bin-abs	1137	1138	3
O	1139	1145	versus
B-iv-bin-abs	1146	1147	1
O	1147	1148	)
O	1148	1149	.

B-outcome	1150	1159	Vasomotor
I-outcome	1160	1168	symptoms
O	1169	1173	were
B-iv-bin-percent	1174	1176	50
I-iv-bin-percent	1176	1177	%
O	1178	1182	more
O	1183	1191	frequent
O	1192	1194	on
O	1195	1204	tamoxifen
O	1204	1205	.

O	1206	1209	The
O	1210	1218	addition
O	1219	1221	of
O	1222	1225	low
O	1225	1226	-
O	1226	1230	dose
O	1231	1240	tamoxifen
O	1241	1243	to
O	1244	1247	HRT
O	1248	1251	did
O	1252	1255	not
O	1256	1269	significantly
O	1270	1276	reduce
O	1277	1283	breast
O	1284	1290	cancer
O	1291	1295	risk
O	1296	1299	and
O	1300	1309	increased
O	1310	1321	climacteric
O	1322	1330	symptoms
O	1331	1333	in
O	1334	1342	recently
O	1343	1357	postmenopausal
O	1358	1363	women
O	1363	1364	.

O	1365	1372	However
O	1372	1373	,
O	1374	1376	we
O	1377	1382	noted
O	1383	1393	beneficial
O	1394	1400	trends
O	1401	1403	in
O	1404	1408	some
O	1409	1418	subgroups
O	1419	1424	which
O	1425	1428	may
O	1429	1436	deserve
O	1437	1438	a
O	1439	1445	larger
O	1446	1451	study
O	1451	1452	.
